EP1007563A4 - Recepteur hm74a - Google Patents

Recepteur hm74a

Info

Publication number
EP1007563A4
EP1007563A4 EP98930215A EP98930215A EP1007563A4 EP 1007563 A4 EP1007563 A4 EP 1007563A4 EP 98930215 A EP98930215 A EP 98930215A EP 98930215 A EP98930215 A EP 98930215A EP 1007563 A4 EP1007563 A4 EP 1007563A4
Authority
EP
European Patent Office
Prior art keywords
hm74a receptor
hm74a
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98930215A
Other languages
German (de)
English (en)
Other versions
EP1007563A1 (fr
Inventor
Nabil A Elshourbagy
Xiaotong Li
Derk J Bergsma
Jeffrey L Mooney
Stephanie F Guerrera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1007563A1 publication Critical patent/EP1007563A1/fr
Publication of EP1007563A4 publication Critical patent/EP1007563A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
EP98930215A 1997-06-12 1998-06-12 Recepteur hm74a Withdrawn EP1007563A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4948097P 1997-06-12 1997-06-12
US49480P 1997-06-12
PCT/US1998/012386 WO1998056820A1 (fr) 1997-06-12 1998-06-12 Recepteur hm74a

Publications (2)

Publication Number Publication Date
EP1007563A1 EP1007563A1 (fr) 2000-06-14
EP1007563A4 true EP1007563A4 (fr) 2003-04-16

Family

ID=21960050

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98930215A Withdrawn EP1007563A4 (fr) 1997-06-12 1998-06-12 Recepteur hm74a

Country Status (4)

Country Link
EP (1) EP1007563A4 (fr)
JP (1) JP2002508660A (fr)
AU (1) AU7966098A (fr)
WO (1) WO1998056820A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119190B2 (en) 1997-04-14 2006-10-10 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human G protein-coupled receptors
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
GB9807722D0 (en) * 1998-04-08 1998-06-10 Smithkline Beecham Plc Novel compounds
AUPP438598A0 (en) 1998-06-29 1998-07-23 Garvan Institute Of Medical Research NPY-Y7 receptor gene
GB9917628D0 (en) * 1999-07-27 1999-09-29 Smithkline Beecham Plc Novel compounds
WO2001036471A2 (fr) * 1999-11-17 2001-05-25 Arena Pharmaceuticals, Inc. Versions endogenes et non-endogenes de recepteurs couples a la proteine g humaine
WO2001073029A2 (fr) * 2000-03-27 2001-10-04 Pe Corporation (Ny) Recepteurs couples aux proteines g humaines isolees, molecules d'acides nucleiques codant les proteines gpcr humaines, et utilisations correspondantes
AU2001246526A1 (en) * 2000-04-05 2001-10-23 Bayer Aktiengesellschaft Regulation of human hm74-like g protein coupled receptor
WO2002002767A1 (fr) * 2000-07-04 2002-01-10 Takeda Chemical Industries, Ltd. Proteine de recepteur couple a la proteine g et adn correspondant
AU2001271025A1 (en) * 2000-07-07 2002-01-21 Takeda Chemical Industries Ltd. Novel g protein-coupled receptor protein and dna thereof
AU2002212140A1 (en) * 2000-08-18 2002-02-25 Novartis Ag Inflammation related g-protein coupled receptor
MXPA03007984A (es) * 2001-03-07 2003-12-04 Bristol Myers Squibb Co Polinucleotido que codifica receptor novedoso acoplado a proteina g humana, hgprbmy27.
AU2002242910A1 (en) * 2001-04-11 2002-10-28 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
US7189524B1 (en) 2002-11-25 2007-03-13 Amgen, Inc. Receptor ligands and methods of modulating receptors
EP1597586A2 (fr) * 2003-02-13 2005-11-23 Bayer HealthCare AG Agents de diagnostic et de traitement destines aux maladies associees a hm74 (hm74)
EP1597587A2 (fr) * 2003-02-17 2005-11-23 Bayer HealthCare AG Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies au recepteur hm74a couple a la proteine g
WO2004083388A2 (fr) 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide codant un nouveau variant de recepteur de hm74, hgprbmy74 couple a une proteine g humaine
WO2005082352A1 (fr) * 2004-02-20 2005-09-09 Aventis Pharmaceuticals Inc. Modulateurs d'oxydecahydronaphtalene de hm74
KR20060127141A (ko) * 2004-02-20 2006-12-11 아벤티스 파마슈티칼스 인크. Ｈｍ74의 조절제로서의 푸로세미드 유도체 및 염증 치료를위한 이의 용도
US20060078916A1 (en) * 2004-08-27 2006-04-13 Luc Aguilar HM74 and HM74a in cuboidal endothelial cells as associated with inflammation
KR101351209B1 (ko) 2004-12-03 2014-02-06 머크 샤프 앤드 돔 코포레이션 Ｃｂ1 길항제로서 치환된 피페라진
PT1901731E (pt) 2005-06-28 2011-05-11 Merck Sharp & Dohme Agonistas de receptor de niacina, composi??es que cont?m tais compostos e m?todos de tratamento
WO2007067912A2 (fr) * 2005-12-07 2007-06-14 Boehringer Ingelheim International Gmbh Traitement et diagnostic de maladies inflammatoires
RU2008133381A (ru) 2006-01-18 2010-02-27 Шеринг Корпорейшн (US) Модуляторы каннабиноидного рецептора
KR20090025262A (ko) 2006-06-23 2009-03-10 인사이트 코포레이션 Ｈｍ７４ａ 아고니스트로서 푸리논 유도체
CN101466714B (zh) 2006-06-23 2013-02-06 英赛特股份有限公司 作为hm74a激动剂的嘌呤酮衍生物
CN101796033A (zh) 2007-06-28 2010-08-04 英特维特国际股份有限公司 作为cb1拮抗剂的取代的哌嗪

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LEE D K ET AL: "DISCOVERY AND MAPPING OF TEN NOVEL G PROTEIN-COUPLED RECEPTOR GENES", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 275, no. 1, 2001, pages 83 - 91, XP004307114, ISSN: 0378-1119 *
NOMURA H ET AL: "Human mRNA for HM74", EMBL ACCESSION NUMBER D10923, 16 July 1992 (1992-07-16), XP002212023 *
See also references of WO9856820A1 *
WISE A ET AL: "Molecular identification of high and low affinity receptors for nicotinic acid", JBC PAPERS IN PRESS, - 9 January 2003 (2003-01-09), XP002231659, Retrieved from the Internet <URL:www.jbc.org/cgi/reprint/M210695200v1> [retrieved on 20030218] *

Also Published As

Publication number Publication date
AU7966098A (en) 1998-12-30
JP2002508660A (ja) 2002-03-19
WO1998056820A1 (fr) 1998-12-17
EP1007563A1 (fr) 2000-06-14

Similar Documents

Publication Publication Date Title
EP1007563A4 (fr) Recepteur hm74a
DE59806556D1 (en) Fmcw-sensor
DE59803915D1 (en) Bandwaage
DE69810944D1 (en) Hydroperoxidzersetzungsverfahren
GB9710773D0 (en) Cytofunnel arrangement
DE59805100D1 (en) Containerbrücke
DE59808840D1 (en) Compoundpumpe
DE59811907D1 (en) Transponder-system
DE69801658D1 (en) Polyurethanhartschaumstoffe
DE69729893D1 (en) Druckbläter
DE59708342D1 (en) Basophilen-degranulationstest
DE69804606D1 (en) Cyclohexandiolderivate
DE69715258D1 (en) Präzisionshydraulikfutter
DE69810074D1 (en) Reaktiver thermoelastischer kryostat
GB9718142D0 (en) Airbags
GB9718143D0 (en) Airbags
DE69812077D1 (en) Anthracyclinglycoside
DE59806884D1 (en) Dexamethason-gel
GB9708589D0 (en) Seurity means
DE69813798D1 (en) Multizyklische erythromycinderivate
DE69737400D1 (en) Substituierte naphthopyrane
DE69735266D1 (en) Substituierte naphthopyrane
DE59811113D1 (en) Laryngoskop
GB9827955D0 (en) Improved weatherbar
DE59809032D1 (en) Telephonsystem

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE DK FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 20030305

17Q First examination report despatched

Effective date: 20030527

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040610